Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Geert Kazemier M

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9811-3497; OpenAlex author ID A5061582249. Sources: OpenAlex.

Their work

Papers
91 (first author 0, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
233
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 3 papers · 2016: 4 papers · 2017: 5 papers · 2018: 2 papers · 2019: 3 papers · 2020: 7 papers · 2021: 6 papers · 2022: 10 papers · 2023: 8 papers · 2024: 15 papers · 2025: 11 papers · 2026: 16 papers

Papers 50 of 91

  1. Transcriptome-Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant T… Co-author DOI 10.1002/ijc.70519↗
  2. Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis. Co-author DOI 10.1007/s00423-026-04291-0↗
  3. Eph receptors in pancreatic cancer: Biological roles and clinical implications. Co-author DOI 10.1016/j.critrevonc.2026.105299↗
  4. Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. Co-author DOI 10.1016/j.ejso.2025.111165↗
  5. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  6. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  7. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  8. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  9. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  10. Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. Co-author DOI 10.1093/oncolo/oyag373↗
  11. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  12. Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment. Co-author DOI 10.1158/0008-5472.can-24-4707↗
  13. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  14. Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18639-1↗
  15. ASO Visual Abstract: Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18791-8↗
  16. Young Age Is Associated with Improved Survival After Resection of Non-Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/life16091499↗
  17. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  18. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  19. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  20. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  21. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  22. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  23. Perineural Invasion is an Important Prognostic Factor in Patients With Radically Resected (R0) and Node-negative (pN0) Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006320↗
  24. Routine Imaging After Resection of Pancreatic Ductal Adenocarcinoma: Nationwide Utilization and Survival Analysis. Co-author DOI 10.1097/sla.0000000000006772↗
  25. Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. Co-author DOI 10.1097/sla.0000000000006910↗
  26. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  27. 18F-Prostate-Specific Membrane Antigen PET/CT imaging for potentially resectable pancreatic cancer (PANSCAN-2): a phase I/II study. Co-author DOI 10.1186/s40644-025-00822-y↗
  28. Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer. Last author DOI 10.1016/j.jlb.2024.100152↗
  29. Association of hypothyroidism with survival in pancreatic cancer: retrospective cohort study. Co-author DOI 10.1093/bjsopen/zrad119↗
  30. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study. Co-author DOI 10.1093/jnci/djae070↗
  31. Artificial Intelligence-based Segmentation of Residual Pancreatic Cancer in Resection Specimens Following Neoadjuvant Treatment (ISGPP-2): International Improv… Co-author DOI 10.1097/pas.0000000000002270↗
  32. Predicting Long-term Disease-free Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Cohort Study. Co-author DOI 10.1097/sla.0000000000006004↗
  33. Poor Prognostic Factors in Long-Term Survivors of Resected Pancreatic Ductal Adenocarcinoma: An International, Multicenter Cohort Study. Co-author DOI 10.1097/sla.0000000000006539↗
  34. In-depth immune profiling of peripheral blood mononuclear cells in patients with pancreatic ductal adenocarcinoma reveals discriminative immune subpopulations. Last author DOI 10.1111/cas.16147↗
  35. Unlocking the diagnostic power of plasma extracellular vesicle miR-200 family in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03090-z↗
  36. Artificial intelligence for assessment of vascular involvement and tumor resectability on CT in patients with pancreatic cancer. Co-author DOI 10.1186/s41747-023-00419-9↗
  37. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Co-author DOI 10.1245/s10434-023-14650-6↗
  38. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone f… Co-author DOI 10.1245/s10434-023-14704-9↗
  39. The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis. Co-author DOI 10.1245/s10434-024-15070-w↗
  40. Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy: A Single-Center Experience. Co-author DOI 10.1245/s10434-024-15591-4↗
  41. Prediction of Isolated Local Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Study. Co-author DOI 10.1245/s10434-024-15664-4↗
  42. The Difficulty of Detecting Occult Metastases in Patients with Potentially Resectable Pancreatic Cancer: Development and External Validation of a Preoperative … Co-author DOI 10.3390/jcm13061679↗
  43. Prediction Model for Early-Stage Pancreatic Cancer Using Routinely Measured Blood Biomarkers. Last author DOI 10.1001/jamanetworkopen.2023.31197↗
  44. Spatial immune composition of tumor microenvironment in patients with pancreatic cancer. Last author DOI 10.1007/s00262-023-03573-6↗
  45. The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer. Last author DOI 10.1007/s00432-023-05219-7↗
  46. Diagnostic accuracy and added value of blood-based protein biomarkers for pancreatic cancer: A meta-analysis of aggregate and individual participant data. Last author DOI 10.1016/j.eclinm.2022.101747↗
  47. Outcome of Pancreatic Surgery During the First 6 Years of a Mandatory Audit Within the Dutch Pancreatic Cancer Group. Co-author DOI 10.1097/sla.0000000000005628↗
  48. hENT1 as a Predictive Biomarker in PDAC-Letter. Last author DOI 10.1158/1078-0432.ccr-22-3827↗
  49. Correction: Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PAN… Co-author DOI 10.1186/s12885-023-10521-1↗
  50. Optimizing patient selection for stereotactic ablative radiotherapy in patients with locally advanced pancreatic cancer after initial chemotherapy - a single c… Co-author DOI 10.3389/fonc.2023.1149961↗

Closest collaborators

The 25 strongest of 233 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 45 shared papers, 2016–2026 · strength 6.54
  2. Elisa Giovannetti · 32 shared papers, 2013–2026 · strength 4.25
  3. Bas Groot Koerkamp · 29 shared papers, 2017–2026 · strength 4.24
  4. Hjalmar C. van Santvoort · 29 shared papers, 2016–2026 · strength 4.10
  5. Izaak Quintus Molenaar · 27 shared papers, 2016–2026 · strength 3.78
  6. Ignace H. J. T. de Hingh · 26 shared papers, 2016–2026 · strength 3.69
  7. Martijn W.J. Stommel · 22 shared papers, 2020–2026 · strength 3.25
  8. Johanna W. Wilmink · 19 shared papers, 2015–2026 · strength 2.98
  9. Lois A. Daamen · 19 shared papers, 2021–2026 · strength 2.83
  10. Sebastiaan Festen · 19 shared papers, 2021–2026 · strength 2.82
  11. Tessa Y. S. Le Large · 21 shared papers, 2015–2026 · strength 2.67
  12. Vincent Erwin de Meijer · 18 shared papers, 2020–2026 · strength 2.61
  13. Bert A. Bonsing · 19 shared papers, 2016–2026 · strength 2.51
  14. Hanneke W.M. van Laarhoven · 17 shared papers, 2017–2026 · strength 2.47
  15. Vincent B. Nieuwenhuijs · 16 shared papers, 2020–2026 · strength 2.25
  16. Casper H.J. van Eijck · 15 shared papers, 2016–2026 · strength 2.16
  17. Laura L. Meijer · 17 shared papers, 2015–2024 · strength 2.01
  18. Iris W.J.M. van Goor · 11 shared papers, 2021–2026 · strength 1.80
  19. Thijs J. Schouten · 12 shared papers, 2021–2026 · strength 1.77
  20. Robert C. Verdonk · 11 shared papers, 2022–2026 · strength 1.65
  21. Lenka N.C. Boyd · 10 shared papers, 2020–2024 · strength 1.63
  22. Freek D. Daams · 10 shared papers, 2017–2026 · strength 1.49
  23. Jisce R. Puik · 8 shared papers, 2021–2025 · strength 1.43
  24. Paul C. M. Andel · 8 shared papers, 2024–2026 · strength 1.41
  25. Maarten F. Bijlsma · 11 shared papers, 2016–2026 · strength 1.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.